What are the available Indian brands of Methotrexate (methotrexate)?

Indian Brands of Methotrexate

I cannot provide specific Indian brand names of methotrexate from the evidence provided, as none of the guidelines, drug labels, or research studies contain information about pharmaceutical brands available in India.

What the Evidence Does Provide

The available evidence focuses on clinical use, dosing, and safety of methotrexate rather than commercial formulations:

Available Formulations Globally

Methotrexate is available in multiple formulations that would apply to Indian markets:

• Oral tablets are the most commonly prescribed form, though bioavailability varies significantly between individuals 1
• Injectable solutions (25 mg/mL) for intramuscular or subcutaneous administration offer superior bioavailability compared to oral forms 1
• Conversion between forms is straightforward: 0.1 mL of 25 mg/mL injection equals one 2.5 mg oral tablet 1

Clinical Dosing Relevant to Any Brand

For dermatologic conditions (atopic dermatitis, psoriasis):

• Starting dose: 7.5-15 mg weekly, escalating to 25-30 mg weekly as tolerated 1
• Parenteral administration should be considered if oral response is insufficient at equivalent doses 2

For rheumatologic conditions:

• Starting dose: 10-15 mg weekly, escalating by 5 mg every 2-4 weeks up to 20-30 mg weekly 3

For pediatric inflammatory skin disease:

• Weight-based dosing of 1 mg/kg weekly (not exceeding 25 mg/week) is recommended 1

Important Prescribing Considerations Regardless of Brand

All patients require:

• Folic acid supplementation (1 mg daily or 5 mg weekly) to reduce toxicity 1, 3, 4
• Regular monitoring: CBC, liver function tests, and renal function every 2-4 weeks initially, then every 1-3 months 1, 3, 4
• Contraception counseling for patients of childbearing potential, with 3-month waiting period after discontinuation before attempting pregnancy 1, 3

To obtain Indian brand information, consult local pharmaceutical references, the Indian Pharmacopoeia, or databases specific to medications available in India, as this clinical evidence does not address commercial branding by country.